Loading
Most hormone-driven breast cancers are cured with surgery, radiotherapy and five to ten years of endocrine tablets. Women whose tumours are larger, higher grade or have reached the lymph nodes face a higher risk of relapse: two to three years of a CDK4/6 inhibitor added to endocrine therapy cuts recurrence, and genomic tests such as Oncotype DX and MammaPrint decide who also needs chemotherapy.
High-risk early disease is defined clinically and genomically. monarchE took node-positive tumours with four or more nodes, or one to three nodes with grade 3, a tumour of 5 cm or more or Ki-67 of 20 percent or more; NATALEE widened the net to stage II and III disease including node-negative stage IIA tumours with high-risk features. Genomic assays sort the rest: TAILORx showed that women over 50 with node-negative tumours and an Oncotype DX recurrence score of 11 to 25 gain nothing from chemotherapy (nine-year invasive disease-free survival 83.3 percent without and 84.3 percent with), RxPONDER showed the same for postmenopausal women with one to three positive nodes and a score up to 25 while premenopausal women still benefited, and MINDACT showed that clinically high-risk tumours with a low MammaPrint score reach 94.7 percent five-year distant metastasis-free survival without chemotherapy.
Endocrine therapy is the backbone. Five years of tamoxifen cuts recurrence and breast cancer death for at least fifteen years, aromatase inhibitors do slightly better in postmenopausal women, and the SOFT and TEXT trials showed that premenopausal women at higher risk do best with ovarian function suppression plus exemestane, with twelve-year disease-free survival of 80.5 percent against 75.9 percent for suppression plus tamoxifen; adding suppression to tamoxifen improved overall survival in the women who had needed chemotherapy. ATLAS and aTTom showed that ten years of tamoxifen beats five, and MA.17 that letrozole after five years of tamoxifen reduces late recurrence, so extended therapy to seven to ten years is offered in node-positive disease at the price of bone loss, joint pain and adherence that falls with every year.
The CDK4/6 inhibitors changed the adjuvant standard. monarchE randomised 5,637 women to two years of abemaciclib with endocrine therapy or endocrine therapy alone and cut invasive recurrence (hazard ratio 0.68), with the gap still widening at five years; NATALEE randomised 5,101 to three years of ribociclib with an aromatase inhibitor (hazard ratio 0.75) and won approval in September 2024. Palbociclib failed twice in the same setting (PALLAS, PENELOPE-B), a reminder that the class does not behave as one drug. Adjuvant olaparib for a year adds survival for germline BRCA carriers (OlympiA), adjuvant giredestrant improved invasive disease-free survival in lidERA in 2025, camizestrant switching is being tested in CAMBRIA, and circulating tumour DNA is being studied to find the women whose late relapse is coming.
Hormone receptor-positive, HER2-negative tumours are about seven in ten breast cancers and most are cured; the high-risk minority with node involvement, large size or high grade account for most of the relapses, which in this subtype can arrive ten or twenty years after diagnosis.
Most cancers start in the ducts and drain first to the axillary nodes, which is why the armpit is checked and a sentinel node is sampled.
Same organ: Triple-negative breast cancer (TNBC), Breast cancer (all types), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Male breast cancer, Ductal carcinoma in situ (DCIS), HR-positive metastatic breast cancer after CDK4/6 inhibitors, HER2-low and HER2-ultralow metastatic breast cancer, Early HER2-positive breast cancer, HER2-positive breast cancer with brain metastases, Early triple-negative breast cancer, Metastatic triple-negative breast cancer, Basal-like 1 triple-negative breast cancer (BL1), Basal-like 2 triple-negative breast cancer (BL2), Mesenchymal triple-negative breast cancer (M), Mesenchymal stem-like triple-negative breast cancer (MSL), Luminal androgen receptor triple-negative breast cancer (LAR), Immunomodulatory triple-negative breast cancer (IM), Metaplastic breast carcinoma, Carcinoma with medullary pattern (medullary breast cancer), Adenoid cystic carcinoma of the breast, Apocrine carcinoma of the breast, Secretory carcinoma of the breast, BRCA-associated triple-negative breast cancer, Inflammatory breast cancer, Paget disease of the nipple, Phyllodes tumour of the breast, Invasive lobular carcinoma of the breast, Invasive breast carcinoma of no special type (invasive ductal carcinoma), Tubular carcinoma of the breast, Mucinous carcinoma of the breast, Papillary carcinomas of the breast (encapsulated, solid and invasive papillary), Invasive cribriform carcinoma of the breast, Invasive micropapillary carcinoma of the breast, Neuroendocrine neoplasms of the breast, Lobular carcinoma in situ (LCIS)
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Genomic assay on node-negative and one to three node-positive tumours; chemotherapy for a high recurrence score, for premenopausal women with node-positive disease and a score up to 25, and for clinically high-risk tumours without a low genomic score.
Aromatase inhibitor for postmenopausal women; tamoxifen, or ovarian function suppression with an aromatase inhibitor for premenopausal women at higher risk (SOFT and TEXT); five years, extended to seven to ten in node-positive disease.
Abemaciclib for two years (monarchE, node-positive high-risk disease) or ribociclib for three years (NATALEE, stage II to III) alongside the aromatase inhibitor.
One year of adjuvant olaparib after chemotherapy for high-risk disease (OlympiA).
Breast-conserving surgery with hypofractionated whole-breast radiotherapy or mastectomy, sentinel node biopsy, and regional nodal irradiation when nodes are involved.
Zoledronic acid or denosumab during aromatase inhibitor therapy in postmenopausal women reduces fractures, and bisphosphonates also reduce bone recurrence.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Ribociclib is a second adjuvant CDK4/6 option, and the only one with data in node-negative stage II disease. Roughly 3 in 100 patients avoid a relapse or death at three years, so the decision depends heavily on individual risk, tolerance of a three-year oral drug, and cost. Whether the benefit persists after treatment ends, as it did with abemaciclib, needs longer follow-up.
Everyone with HER2-negative early breast cancer that meets high-risk criteria should be offered germline BRCA testing, because a positive result now changes treatment: a year of olaparib after chemotherapy reduces relapse and death. It does not apply to low-risk tumours, HER2-positive disease, or somatic-only BRCA mutations.
Women with hormone-receptor-positive, HER2-negative breast cancer that has spread to lymph nodes and has other high-risk features can now be offered two years of abemaciclib alongside their hormone therapy, with a durable reduction in relapse. It does not apply to node-negative or low-risk disease, and the diarrhoea and cost are real trade-offs to discuss.
Most women with node-negative hormone receptor-positive breast cancer can safely skip chemotherapy on the basis of a genomic assay; the exception is premenopausal women with scores in the upper part of the intermediate range.
Query for this cancer: (TITLE:"High-risk early HR-positive breast cancer" OR ABSTRACT:"High-risk early HR-positive breast cancer" OR TITLE:"High-risk early hormone receptor-positive, HER2-negative breast cancer" OR ABSTRACT:"High-risk early hormone receptor-positive, HER2-negative breast cancer" OR TITLE:"Node-positive luminal breast cancer" OR ABSTRACT:"Node-positive luminal breast cancer" OR TITLE:"Stage II to III HR-positive breast cancer" OR ABSTRACT:"Stage II to III HR-positive breast cancer") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about High-risk early HR-positive breast cancer, not a curated reading list.
The targets of this cancer's medicines and the ones linked to it directly.
Cases by country, the UK and NHS pathway and other country lenses, the expert centres with trials on record, and the centres named on this cancer's subtypes.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
A swollen painful calf, or sudden breathlessness with chest pain; the tamoxifen boxed warning covers pulmonary embolism and stroke.
Fainting, dizziness or an irregular heartbeat; QT prolongation is a labelled warning and ECGs are checked in the first cycles.
A swollen painful calf, or sudden breathlessness with chest pain; venous thromboembolism including pulmonary embolism is a labelled warning.
Additive QT prolongation; ribociclib is not recommended with tamoxifen.. Use an aromatase inhibitor or fulvestrant instead.
Avoid grapefruit. Diarrhoea: start loperamide at the first loose stool.
Take after a meal.
See all on the product pages:AbemaciclibExemestaneGoserelin / leuprolide (ovarian function suppression)Letrozole (and other aromatase inhibitors)OlaparibRibociclibTamoxifen·Printable cards in the navigator
Newly diagnosed? Read the first 60 days with High-risk early HR-positive breast cancer, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.